XML 32 R20.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment Information and Concentration of Business Risk (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Segment Information and Concentration of Business Risk [Abstract] |
Segment Information | The following tables show our segment revenue and income (loss) from operations for the three and nine months ended September 30, 2018 and 2017 (in thousands), respectively.
Three Months Ended September 30, 2018 |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Commercial revenue: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA royalties |  | $ | 70,010 |  |  | $ | — |  |  | $ | — |  |  | $ | 70,010 |
Licensing and other royalty revenue |  |  | 7,946 |  |  |  | 12,000 |  |  |  | (7,200 | ) |  |  | 12,746 |
Total commercial revenue |  |  | 77,956 |  |  |  | 12,000 |  |  |  | (7,200 | ) |  |  | 82,756 |
R&D revenue under collaborative agreements |  |  | 100,105 |  |  |  | 7,241 |  |  |  | (44,707 | ) |  |  | 62,639 |
Total segment revenue |  | $ | 178,061 |  |  | $ | 19,241 |  |  | $ | (51,907 | ) |  | $ | 145,395 |
Total operating expenses |  | $ | 87,664 |  |  | $ | 84,249 |  |  | $ | (7,946 | ) |  | $ | 163,967 |
Income (loss) from operations |  | $ | 90,397 |  |  | $ | (65,008 | ) |  | $ | (43,961 | ) |  | $ | (18,572 | )
Three Months Ended September 30, 2017 (as revised) |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Commercial revenue: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA royalties |  | $ | 32,890 |  |  | $ | — |  |  | $ | — |  |  | $ | 32,890 |
Licensing and other royalty revenue |  |  | 1,727 |  |  |  | — |  |  |  | — |  |  |  | 1,727 |
Total commercial revenue |  |  | 34,617 |  |  |  | — |  |  |  | — |  |  |  | 34,617 |
R&D revenue under collaborative agreements |  |  | 73,791 |  |  |  | 9,906 |  |  |  | — |  |  |  | 83,697 |
Total segment revenue |  | $ | 108,408 |  |  | $ | 9,906 |  |  | $ | — |  |  | $ | 118,314 |
Total operating expenses |  | $ | 81,019 |  |  | $ | 26,013 |  |  | $ | (30 | ) |  | $ | 107,002 |
Income (loss) from operations |  | $ | 27,389 |  |  | $ | (16,107 | ) |  | $ | 30 |  |  | $ | 11,312 |
Nine Months Ended September 30, 2018 |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Commercial revenue: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA royalties |  | $ | 167,743 |  |  | $ | — |  |  | $ | — |  |  | $ | 167,743 |
Licensing and other royalty revenue |  |  | 9,432 |  |  |  | 12,000 |  |  |  | (7,200 | ) |  |  | 14,232 |
Total commercial revenue |  |  | 177,175 |  |  |  | 12,000 |  |  |  | (7,200 | ) |  |  | 181,975 |
R&D revenue under collaborative agreements |  |  | 232,850 |  |  |  | 42,670 |  |  |  | (49,936 | ) |  |  | 225,584 |
Total segment revenue |  | $ | 410,025 |  |  | $ | 54,670 |  |  | $ | (57,136 | ) |  | $ | 407,559 |
Total operating expenses |  | $ | 279,084 |  |  | $ | 213,428 |  |  | $ | (12,796 | ) |  | $ | 479,716 |
Income (loss) from operations |  | $ | 130,941 |  |  | $ | (158,758 | ) |  | $ | (44,340 | ) |  | $ | (72,157 | )
Nine Months Ended September 30, 2017 (as revised) |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Commercial revenue: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA royalties |  | $ | 60,467 |  |  | $ | — |  |  | $ | — |  |  | $ | 60,467 |
Licensing and other royalty revenue |  |  | 5,639 |  |  |  | — |  |  |  | — |  |  |  | 5,639 |
Total commercial revenue |  |  | 66,106 |  |  |  | — |  |  |  | — |  |  |  | 66,106 |
R&D revenue under collaborative agreements |  |  | 312,976 |  |  |  | 21,712 |  |  |  | (54,407 | ) |  |  | 280,281 |
Total segment revenue |  | $ | 379,082 |  |  | $ | 21,712 |  |  | $ | (54,407 | ) |  | $ | 346,387 |
Total operating expenses |  | $ | 242,753 |  |  | $ | 120,884 |  |  | $ | (54,497 | ) |  | $ | 309,140 |
Income (loss) from operations |  | $ | 136,329 |  |  | $ | (99,172 | ) |  | $ | 90 |  |  | $ | 37,247 |
The following table shows our total assets by segment at September 30, 2018 and December 31, 2017 (in thousands), respectively.
Total Assets |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
September 30, 2018 |  | $ | 2,446,425 |  |  | $ | 379,128 |  |  | $ | (577,641 | ) |  | $ | 2,247,913 |
December 31, 2017 (as revised) |  | $ | 1,342,578 |  |  | $ | 268,804 |  |  | $ | (288,608 | ) |  | $ | 1,322,774 |
Revenue from Significant Partners | We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
|  |  |  |  | (as revised) |  |  |  |  |  | (as revised)
Partner A |  | 72% |  |  | 74% |  |  | 58% |  |  | 57%
Partner B |  | 10% |  |  | 4% |  |  | 21% |  |  | 4%
Partner C |  | 5% |  |  | 8% |  |  | 10% |  |  | 6%
Partner D |  | 8% |  |  | 0% |  |  | 3% |  |  | 0%
Partner E |  | 1% |  |  | 0% |  |  | 1% |  |  | 19%

X
- Definition Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + References No definition available. + Details
Name: | us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration